Literature DB >> 16148529

Effects of probiotics on the gastrointestinal tract.

Anna M Snelling1.   

Abstract

PURPOSE OF REVIEW: This review summarizes recent developments in our understanding of what gastrointestinal disorders probiotics can be of benefit for, focussing on conditions associated with infection or disruption of the normal gut flora. New insights into the effects administered strains can have in the gut, their safety, and potential for future development, will also be discussed. RECENT
FINDINGS: Recent clinical studies have shown that probiotics can protect young children from diarrhoeal illness, including antibiotic-associated diarrhoea. They may also protect neonates from necrotizing enterocolitis. In adults, they can help prevent or reduce the severity of diarrhoeal illness, and ameliorate side-effects for those undergoing antibiotic therapy for infection. Researchers are looking at combining probiotics with prebiotics to enhance anti-inflammatory effects and restore colonization resistance of the commensal flora. New technologies are elucidating complex effects on gene expression in the gut, the probiotic, and bacterial pathogens. Recombinant strains capable of binding bacterial toxins are being developed as novel therapeutics against gastrointestinal infection.
SUMMARY: Considering the clinical trial evidence of therapeutic benefit, probiotics are an underused treatment modality for prevention and amelioration of diarrhoeal illness. Better understanding of strain-specific effects, dosing regimens and any contraindications should help resolve this.

Entities:  

Mesh:

Year:  2005        PMID: 16148529     DOI: 10.1097/01.qco.0000182103.32504.e3

Source DB:  PubMed          Journal:  Curr Opin Infect Dis        ISSN: 0951-7375            Impact factor:   4.915


  11 in total

Review 1.  Microbiota and pathogen 'pas de deux': setting up and breaking down barriers to intestinal infection.

Authors:  Elizabeth S McKenney; Melissa M Kendall
Journal:  Pathog Dis       Date:  2016-05-31       Impact factor: 3.166

Review 2.  Probiotic use in irritable bowel syndrome.

Authors:  Patrick Young; Brooks D Cash
Journal:  Curr Gastroenterol Rep       Date:  2006-08

3.  Selecting lactic acid bacteria for their safety and functionality by use of a mouse colitis model.

Authors:  Catherine Daniel; Sabine Poiret; Denise Goudercourt; Veronique Dennin; Gregory Leyer; Bruno Pot
Journal:  Appl Environ Microbiol       Date:  2006-09       Impact factor: 4.792

Review 4.  The dual role of bacteriocins as anti- and probiotics.

Authors:  O Gillor; A Etzion; M A Riley
Journal:  Appl Microbiol Biotechnol       Date:  2008-10-14       Impact factor: 4.813

5.  Effect of molecules secreted by Lactobacillus acidophilus strain La-5 on Escherichia coli O157:H7 colonization.

Authors:  Maira J Medellin-Peña; Mansel W Griffiths
Journal:  Appl Environ Microbiol       Date:  2008-12-16       Impact factor: 4.792

6.  A randomized double-blind trial on perioperative administration of probiotics in colorectal cancer patients.

Authors:  Luca Gianotti; Lorenzo Morelli; Francesca Galbiati; Simona Rocchetti; Sara Coppola; Aldo Beneduce; Cristina Gilardini; Daniela Zonenschain; Angelo Nespoli; Marco Braga
Journal:  World J Gastroenterol       Date:  2010-01-14       Impact factor: 5.742

7.  Common occurrence of antibacterial agents in human intestinal microbiota.

Authors:  Fatima Drissi; Sylvain Buffet; Didier Raoult; Vicky Merhej
Journal:  Front Microbiol       Date:  2015-05-07       Impact factor: 5.640

8.  Production of biologically active human interleukin-10 by Bifidobacterium bifidum BGN4.

Authors:  Nayoun Hong; Seockmo Ku; Kyungjin Yuk; Tony V Johnston; Geun Eog Ji; Myeong Soo Park
Journal:  Microb Cell Fact       Date:  2021-01-19       Impact factor: 5.328

9.  BACTIBASE: a new web-accessible database for bacteriocin characterization.

Authors:  Riadh Hammami; Abdelmajid Zouhir; Jeannette Ben Hamida; Ismail Fliss
Journal:  BMC Microbiol       Date:  2007-10-17       Impact factor: 3.605

10.  Intranasal Application of Lactococcus lactis W136 Is Safe in Chronic Rhinosinusitis Patients With Previous Sinus Surgery.

Authors:  Leandra Mfuna Endam; Saud Alromaih; Emmanuel Gonzalez; Joaquin Madrenas; Benoit Cousineau; Axel E Renteria; Martin Desrosiers
Journal:  Front Cell Infect Microbiol       Date:  2020-10-12       Impact factor: 5.293

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.